Patient on life support in ICU

A new study shows that critically ill patients are not benefitting from antipsychotic medications that doctors have been using to treat delirium in patients in intensive care units. The evidence suggests doctors may need to re-examine the practice. Regenstrief investigator Babar Khan, M.D., was a co-author on the study.

Each year, more than seven million hospitalized patients in the United States develop delirium. The acute brain failure results in confusion and long-term memory problems.

The large study, MIND-USA (Modifying the INcidence of Delirium), sought to answer whether typical and atypical antipsychotics — haloperidol or ziprasidone — affected delirium, survival, length of stay or safety in ICU patients. Researchers screened nearly 21,000 patients at 16 U.S. medical centers. Of the 1,183 patients on mechanical ventilation or in shock, 566 became delirious and were randomized into groups receiving either intravenous haloperidol, ziprasidone or placebo (saline). Results showed that patients who received the drugs did not experience any improvements whatsoever in delirium, coma, length of stay or survival.

Study authors say the medicines are bringing risk and cost without benefit, based on the outcomes measured in this study. Doctors have been prescribing the drugs for 40 years.

Dr. Khan, who worked on this study, has conducted extensive studies on treating and preventing delirium. He led a project at Regenstrief that developed and validated the Confusion Assessment Method for the Intensive Care Unit 7. It’s an easy-to-use method to determine the severity of delirium.

The MIND-USA study was published in the New England Journal of Medicine. It was funded by the National Institute on Aging.

Related News

Oct 16, 2019 • News
Regenstrief leaders to deliver keynote addresses at data workshop in South America
Two of Regenstrief Institute’s leaders are sharing their expertise in artificial intelligence and data infrastructure at a workshop hosted by Brazil’s National Institute of Science and Technology in Scientific Assisted Medicine in Sao Paulo, Brazil. Regenstrief’s Vice President for Research, Eneida Mendonca, M.D., PhD, will speak Thursday, Oct. 17 and Friday, Oct. 18, about the…
Continue Reading >
Oct 15, 2019 • News
Acceptance and commitment therapy may ease fear of recurrence in cancer survivors
Acceptance and commitment therapy (ACT) shows promise for treating fear of cancer recurrence in women who have survived breast cancer. The first of its kind study by researchers from Regenstrief Institute, Indiana University, Butler University and West Virginia University School of Medicine, published in Cancer, found that cancer survivors who received ACT showed significantly larger…
Continue Reading >